A Phase I/II Study of TRS005 in Combination With Cyclophosphamide, Doxorubicin, and Prednisone（T-CHP） in Previously Untreated Patients With CD20-positive DLBCL

NCT07035379 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

NOT_YET_RECRUITING

Status

66

Enrollment

INDUSTRY

Sponsor class

Conditions

Diffuse Large B-Cell Lymphoma (DLBCL)

Interventions

DRUG: TRS005
DRUG: Cyclophosphamide
DRUG: Doxorubicin
DRUG: Prednisolone

Sponsor

Zhejiang Teruisi Pharmaceutical Inc.